TMCnet News

Research and Markets: Global Proliferative Diabetic Retinopathy (PDR) Therapeutics Pipeline Review 2015
[November 27, 2015]

Research and Markets: Global Proliferative Diabetic Retinopathy (PDR) Therapeutics Pipeline Review 2015


Research and Markets (http://www.researchandmarkets.com/research/8tn4jl/proliferative) has announced the addition of the "Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Proliferative Diabetic Retinopathy (PDR), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule tpe, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Proliferative Diabetic Retinopathy (PDR) and special features on late-stage and discontinued projects.



The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development


  • Antisense Therapeutics Limited
  • Icon Bioscience, Inc.
  • OcuCure Therapeutics, Inc.
  • Ohr Pharmaceutical Inc.
  • Ribomic Inc.
  • Sirnaomics, Inc.
  • ThromboGenics NV

For more information visit http://www.researchandmarkets.com/research/8tn4jl/proliferative


[ Back To TMCnet.com's Homepage ]